Funding Supports Development of Oxford Endovascular’s Flow Diverter to Treat Brain Aneurysms


February 11, 2016—Isis Innovation, the research and technology commercialization company of the University of Oxford in the United Kingdom, announced last month that an Oxford spin-out company is developing advanced devices invented at the University to treat patients with brain aneurysms. 

Oxford Endovascular has raised £2 million from investment company Oxford Sciences Innovation PLC, the University of Oxford Isis Fund, and other private investors to take the device through clinical trials and worldwide commercialization.

According to Isis Innovation, the Oxford technology uses a special laser-cut metal alloy that has shape memory. It can be posted into a catheter during surgery, inserted into the brain, and opened up into a flow diverter, a tiny mesh tube that fits into the natural shape of the blood vessel. This diverts the blood away from the aneurysm, allowing it to heal.

The Oxford Endovascular device will allow physicians to place the device more accurately and in a wider range of patients for safer and more effective treatment than current devices provide. The company says its aim is to allow physicians to treat deeper brain blood vessels not accessible with existing devices.

Isis Innovation noted that the Oxford inventors, James Byrne, MD, a Professor of Neuroradiology at the John Radcliffe Hospital, and Zhong You, PhD, a Professor in the Department of Engineering Science, designed the device after observing the limitations of existing treatments. Isis Innovation supported the team by filing patents, building the business plan, and marketing the opportunity.

Oxford Endovascular aims to complete development and begin manufacturing the device before moving into clinical trials and applying for regulatory approval in major markets.


Contact Info

For advertising rates and opportunities, contact:
Craig McChesney

Stephen Hoerst

Charles Philip

About Endovascular Today

Endovascular Today is a publication dedicated to bringing you comprehensive coverage of all the latest technology, techniques, and developments in the endovascular field. Our Editorial Advisory Board is composed of the top endovascular specialists, including interventional cardiologists, interventional radiologists, vascular surgeons, neurologists, and vascular medicine practitioners, and our publication is read by an audience of more than 22,000 members of the endovascular community.